Compare IAG & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IAG | IMVT |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 8.0B |
| IPO Year | 2002 | 2019 |
| Metric | IAG | IMVT |
|---|---|---|
| Price | $15.12 | $39.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $17.75 | ★ $33.00 |
| AVG Volume (30 Days) | ★ 4.6M | 1.4M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.70 | N/A |
| Revenue Next Year | $1.11 | N/A |
| P/E Ratio | $18.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.69 | $14.32 |
| 52 Week High | $24.87 | $41.23 |
| Indicator | IAG | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 57.81 |
| Support Level | $14.78 | $37.53 |
| Resistance Level | $15.80 | $41.23 |
| Average True Range (ATR) | 0.61 | 1.43 |
| MACD | -0.02 | -0.29 |
| Stochastic Oscillator | 43.10 | 47.70 |
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.